학술논문
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Document Type
Article
Author
Sridhar, Saranya ; Joaquin, Arnel; Bonaparte, Matthew I; Bueso, Agustin; Chabanon, Anne-Laure; Chen, Aiying; Chicz, Roman M; Diemert, David; Essink, Brandon J; Fu, Bo; Grunenberg, Nicole A; Janosczyk, Helene; Keefer, Michael C; Rivera M, Doris M; Meng, Ya; Michael, Nelson L; Munsiff, Sonal S; Ogbuagu, Onyema; Raabe, Vanessa N; Severance, Randall; Rivas, Enrique; Romanyak, Natalya; Rouphael, Nadine G; Schuerman, Lode; Sher, Lawrence D; Walsh, Stephen R; White, Judith; von Barbier, Dalia; de Bruyn, Guy; Canter, Richard; Grillet, Marie-Helene; Keshtkar-Jahromi, Maryam; Koutsoukos, Marguerite; Lopez, Denise; Masotti, Roger; Mendoza, Sandra; Moreau, Catherine; Ceregido, Maria Angeles; Ramirez, Shelly; Said, Ansoyta; Tavares-Da-Silva, Fernanda; Shi, Jiayuan; Tong, Tina; Treanor, John; Diazgranados, Carlos A; Savarino, Stephen
Source
In The Lancet Infectious Diseases May 2022 22(5):636-648
Subject
Language
ISSN
1473-3099